Evidence map›Paper›PMID 25216251›Full record

ArticlePloS one2014

IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.

Kimberly A Negrin, Rachel J Roth Flach, Marina T DiStefano, Anouch Matevossian, Randall H Friedline, DaeYoung Jung, Jason K Kim, Michael P Czech

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 164 citations in OpenAlex.

  1. Article
  2. [Alcohol liver disease: immunoregulatory mechanisms and precision therapeutic targets].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. IL-1 family of cytokines in gastrointestinal and liver disorders.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  7. Article
  8. IL-1 family cytokines in inflammation and immunity.Cellular & molecular immunology · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. HFD Exacerbates Hepatic Lipid Metabolism Disorders After Cholecystectomy by Regulating the Bile Acid and Neutrophil Recruitment.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. ACS omega · 2024
    Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kimberly A NegrinProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Rachel J Roth FlachProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Marina T DiStefanoProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Anouch MatevossianProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Randall H FriedlineProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America; Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
DaeYoung JungProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America; Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Jason K KimProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America; Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Michael P CzechProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
University of Massachusetts Chan Medical School · US

Funding

Virology and Technology CoreP01AI046629 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 1999 to 2014
$19.1M
Oral Delivery Vehicles for RNAi TherapiesR01DK085753 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 2009 to 2013
$5.9M
UMass Mouse Metabolic Phenotyping CenterU24DK093000 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIM, JASON K · 2011 to 2015
$2.1M
NIAID NIH HHS AI046629NIAID NIH HHS P01 AI046629NIDDK NIH HHS DK085753NIDDK NIH HHS DK325220NIDDK NIH HHS R01 DK085753NIDDK NIH HHS U24 DK093000
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease is prevalent in human obesity and type 2 diabetes, and is characterized by increases in both hepatic triglyceride accumulation (denoted as steatosis) and expression of pro-inflammatory cytokines such as IL-1β. We report here that the development of hepatic steatosis requires IL-1 signaling, which upregulates Fatty acid synthase to promote hepatic lipogenesis. Using clodronate liposomes to selectively deplete liver Kupffer cells in ob/ob mice, we observed remarkable amelioration of obesity-induced hepatic steatosis and reductions in liver weight, triglyceride content and lipogenic enzyme expressions. Similar results were obtained with diet-induced obese mice, although visceral adipose tissue macrophage depletion also occurred in response to clodronate liposomes in this model. There were no differences in the food intake, whole body metabolic parameters, serum β-hydroxybutyrate levels or lipid profiles due to clodronate-treatment, but hepatic cytokine gene expressions including IL-1β were decreased. Conversely, treatment of primary mouse hepatocytes with IL-1β significantly increased triglyceride accumulation and Fatty acid synthase expression. Furthermore, the administration of IL-1 receptor antagonist to obese mice markedly reduced obesity-induced steatosis and hepatic lipogenic gene expression. Collectively, our findings suggest that IL-1β signaling upregulates hepatic lipogenesis in obesity, and is essential for the induction of pathogenic hepatic steatosis in obese mice.

Indexed as

AnimalsFatty Acid Synthase, Type IFatty LiverGene ExpressionHepatocytesHumansInterleukin-1betaKupffer CellsLipogenesisMiceMice, ObeseObesityReceptors, Interleukin-1Signal TransductionFatty Acid Synthase, Type IIL1B protein, mouseInterleukin-1betaReceptors, Interleukin-1

Identifiers

PMID25216251
PMCPMC4162604
OpenAlexW2051327133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.